MX2021014686A - Métodos y usos para tratar el cáncer. - Google Patents
Métodos y usos para tratar el cáncer.Info
- Publication number
- MX2021014686A MX2021014686A MX2021014686A MX2021014686A MX2021014686A MX 2021014686 A MX2021014686 A MX 2021014686A MX 2021014686 A MX2021014686 A MX 2021014686A MX 2021014686 A MX2021014686 A MX 2021014686A MX 2021014686 A MX2021014686 A MX 2021014686A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- treat cancer
- cancer
- subject
- hhi
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962853842P | 2019-05-29 | 2019-05-29 | |
| PCT/US2020/070080 WO2020243745A1 (en) | 2019-05-29 | 2020-05-28 | Methods and uses for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021014686A true MX2021014686A (es) | 2022-04-06 |
Family
ID=73553943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021014686A MX2021014686A (es) | 2019-05-29 | 2020-05-28 | Métodos y usos para tratar el cáncer. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11911374B2 (https=) |
| EP (1) | EP3976036A4 (https=) |
| JP (2) | JP2022543021A (https=) |
| KR (1) | KR20220002745A (https=) |
| CN (2) | CN119326899A (https=) |
| AU (1) | AU2020283913A1 (https=) |
| BR (1) | BR112021026294A2 (https=) |
| CA (1) | CA3141072A1 (https=) |
| IL (1) | IL288591B1 (https=) |
| MX (1) | MX2021014686A (https=) |
| WO (1) | WO2020243745A1 (https=) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170326118A1 (en) * | 2001-07-02 | 2017-11-16 | Sinan Tas | Drug treatment of tumors wherein hedgehog/smoothened signaling is utilized for inhibition of apoptosis of tumor cells |
| MY150379A (en) * | 2008-02-26 | 2013-12-31 | Takeda Pharmaceutical | Fused heterocyclic derivative and use thereof |
| PL2470173T3 (pl) * | 2009-08-25 | 2016-11-30 | Leczenie skojarzone nanocząstkowymi kompozycjami taksanu i inhibitorów hedgehog | |
| WO2011156119A1 (en) | 2010-06-07 | 2011-12-15 | Abraxis Bioscience, Llc | Combination therapy methods for treating proliferative diseases |
| JP2012097032A (ja) * | 2010-11-02 | 2012-05-24 | Takeda Chem Ind Ltd | 併用医薬 |
| WO2014165644A2 (en) * | 2013-04-04 | 2014-10-09 | The General Hospital Corporation | Combination treatments with sonic hedgehog inhibitors |
| WO2015073691A1 (en) * | 2013-11-14 | 2015-05-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treating cancer by activation of bmp signaling |
| US10329304B2 (en) * | 2014-09-12 | 2019-06-25 | Vanderbilt University | Compounds and methods for inhibition of hedgehog signaling and phosphodiesterase |
| WO2016141084A1 (en) * | 2015-03-03 | 2016-09-09 | The Board Of Trustees Of The Leland Stanford Junior University | Producing mesodermal cell types and methods of using the same |
| US11026889B2 (en) * | 2015-12-09 | 2021-06-08 | Board Of Regents, The University Of Texas System | Polymeric drug delivery systems for treatment of disease |
| CN108853507A (zh) * | 2017-05-11 | 2018-11-23 | 复旦大学 | 一种抗肿瘤的增效药物组合物及其制备方法和用途 |
| US20200368246A1 (en) * | 2017-11-17 | 2020-11-26 | Jaeyoung Yoon | Combination therapy targeting cancer associated with the hedgehog pathway |
-
2020
- 2020-05-28 WO PCT/US2020/070080 patent/WO2020243745A1/en not_active Ceased
- 2020-05-28 MX MX2021014686A patent/MX2021014686A/es unknown
- 2020-05-28 EP EP20814240.6A patent/EP3976036A4/en active Pending
- 2020-05-28 KR KR1020217042915A patent/KR20220002745A/ko active Pending
- 2020-05-28 CN CN202410646745.9A patent/CN119326899A/zh active Pending
- 2020-05-28 CA CA3141072A patent/CA3141072A1/en active Pending
- 2020-05-28 CN CN202080050914.2A patent/CN114126656A/zh active Pending
- 2020-05-28 JP JP2022506342A patent/JP2022543021A/ja active Pending
- 2020-05-28 AU AU2020283913A patent/AU2020283913A1/en not_active Abandoned
- 2020-05-28 BR BR112021026294A patent/BR112021026294A2/pt unknown
-
2021
- 2021-01-20 US US17/153,345 patent/US11911374B2/en active Active
- 2021-12-01 IL IL288591A patent/IL288591B1/en unknown
-
2025
- 2025-06-04 JP JP2025093180A patent/JP2025143272A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3976036A4 (en) | 2023-04-26 |
| WO2020243745A1 (en) | 2020-12-03 |
| CA3141072A1 (en) | 2020-12-03 |
| EP3976036A1 (en) | 2022-04-06 |
| CN119326899A (zh) | 2025-01-21 |
| CN114126656A (zh) | 2022-03-01 |
| KR20220002745A (ko) | 2022-01-06 |
| BR112021026294A2 (pt) | 2022-03-03 |
| JP2025143272A (ja) | 2025-10-01 |
| IL288591B1 (en) | 2026-01-01 |
| US11911374B2 (en) | 2024-02-27 |
| IL288591A (en) | 2022-02-01 |
| US20220071982A1 (en) | 2022-03-10 |
| AU2020283913A1 (en) | 2022-01-27 |
| JP2022543021A (ja) | 2022-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022013777A2 (es) | Uso de agentes para el tratamiento de condiciones respiratorias | |
| MX2023007193A (es) | Inhibidores de enpp1 y su uso para el tratamiento del cancer. | |
| CL2020002512A1 (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak. | |
| MX394252B (es) | Tratamiento del cancer usando combinaciones de inhibidores de erk y raf | |
| CL2021002533A1 (es) | Composiciones y métodos para el tratamiento de enfermedades o trastornos asociados con kras | |
| MX2020008906A (es) | Compuestos con actividad inductora de ferroptosis y métodos de uso de estos. | |
| MX2019003703A (es) | Método seguro y eficaz para tratar la psoriasis con el anticuerpo específico anti-il23. | |
| MX2020011727A (es) | Terapia adjuntiva con 25-hidroxi vitamina d y artículos de los mismos. | |
| MX2016015434A (es) | Combinaciones farmaceuticas para tratar cancer. | |
| AR116121A1 (es) | Métodos de tratamiento del cáncer | |
| EP4389225A3 (en) | Cancer treatments using combinations of type 2 mek and erk inhibitors | |
| WO2018102687A3 (en) | Combination therapy for treating cancer | |
| MX387658B (es) | Métodos para tratar y/o prevenir queratosis actínica. | |
| MX2018012165A (es) | Metodos de tratamiento de canceres pediatricos. | |
| CL2021001623A1 (es) | Terapia de combinación con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cáncer | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| WO2015095838A3 (en) | Cancer treatments using combinations of mek type i and erk inhibitors | |
| WO2021041539A3 (en) | Pyrido-indole analogues as gpx4 inhibitors | |
| MX2021007565A (es) | Composiciones y metodos para la terapia contra el cancer. | |
| CL2019002325A1 (es) | Combinaciones farmacéuticas para tratar cáncer. | |
| CL2021003170A1 (es) | Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa | |
| CL2022000790A1 (es) | Método para tratar vih con cabotegravir y rilpivirina | |
| MX2024003258A (es) | Inhibidores de ribonucleotido reductasa (rnr) de sulfonamida ciclica y usos de los mismos. | |
| CL2022001458A1 (es) | Método para el tratamiento de cáncer utilizando célula ad-yuvante artificial (aavc) | |
| ZA202103914B (en) | Cxcr7 inhibitors for the treatment of cancer |